Northern Trust’s Lantern Pharma LTRN Stock Holding History

Northern Trust’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.9K	Buy	17,485 +1,896	+12%	+$5.56K	﹤0.01%	4195
2026 Q1	$21.4K	Hold	15,589	–	–	﹤0.01%	4332
2025 Q4	$47.2K	Hold	15,589	–	–	﹤0.01%	4290
2025 Q3	$67.8K	Hold	15,589	–	–	﹤0.01%	4224
2025 Q2	$49.3K	Hold	15,589	–	–	﹤0.01%	4237
2025 Q1	$55.2K	Buy	15,589 +2,776	+22%	+$11.5K	﹤0.01%	4220
2024 Q4	$40.9K	Hold	12,813	–	–	﹤0.01%	4288
2024 Q3	$47K	Hold	12,813	–	–	﹤0.01%	4225
2024 Q2	$59.8K	Sell	12,813 -10	-0.1%	-$60	﹤0.01%	4179
2024 Q1	$113K	Buy	12,823 +230	+2%	+$1.23K	﹤0.01%	4047
2023 Q4	$53.9K	Hold	12,593	–	–	﹤0.01%	4224
2023 Q3	$42.9K	Hold	12,593	–	–	﹤0.01%	4201
2023 Q2	$71K	Sell	12,593 -36	-0.3%	-$186	﹤0.01%	4129
2023 Q1	$61K	Hold	12,629	–	–	﹤0.01%	4212
2022 Q4	$76.3K	Hold	12,629	–	–	﹤0.01%	4178
2022 Q3	$60K	Hold	12,629	–	–	﹤0.01%	4279
2022 Q2	$72K	Hold	12,629	–	–	﹤0.01%	4292
2022 Q1	$90K	Hold	12,629	–	–	﹤0.01%	4381
2021 Q4	$101K	Hold	12,629	–	–	﹤0.01%	4422
2021 Q3	$141K	Hold	12,629	–	–	﹤0.01%	4311
2021 Q2	$184K	Hold	12,629	–	–	﹤0.01%	4188
2021 Q1	$229K	Buy	+12,629	New	+$221K	﹤0.01%	4066

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Northern Trust's LTRN Position: Q2 2026 in Review

Northern Trust increased its Lantern Pharma (LTRN) stake by 12% in Q2 2026, buying an estimated $5.56K and bringing the position to 17,485 shares worth $72.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4195.

Northern Trust first reported a position in LTRN in Q1 2021 and has held it in 22 quarters since. The position peaked at $229K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Northern Trust held 17,485 shares of Lantern Pharma worth $72.9K as of Q2 2026.
Northern Trust bought 1,896 Lantern Pharma shares in Q2 2026, an estimated $5.56K.
Lantern Pharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4195 holding.
Northern Trust first reported a position in Lantern Pharma in Q1 2021 and has held it in 22 quarters since.
Northern Trust's Lantern Pharma position peaked at $229K in Q1 2021.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.